In brief
- On October 1, 2026, Canada’s new Controlled Substances Regulations went into effect, consolidating several previous rules into a single text.
- The regulations incorporate authorizations from a class exemption that previously covered activities involving psilocybin and MDMA obtained through the Special Access Program.
- Psilocybin, psilocin, DMT, and mescaline are listed in Schedule 4, the category for “restricted drugs.”
As of October 1, Canada has implemented a single regulation for controlled substances, SOR/2025-242. It replaces several previous rules, including Parts G and J of the Food and Drug Regulations, which until now governed “restricted” psychedelics in research. The text also incorporates the authorizations that Health Canada previously granted via exemptions to work with psilocybin and MDMA.
A single text instead of several
The regulation was registered on November 28, 2025, and published in the Canada Gazette on December 17, 2025, with an effective date of October 1, 2026. Its impact analysis explains that the delay was intended to give regulated parties time to prepare. It repeals the Narcotic Control Regulations, the Benzodiazepine and Other Targeted Substances Regulations, Parts G and J of the Food and Drug Regulations, and the New Classes of Practitioners Regulations, among others.
According to the document, Part J previously established the framework for producing, distributing, importing, exporting, or researching restricted drugs, such as psilocybin or LSD, for scientific purposes. Since those substances had no approved therapeutic uses, it did not contain provisions for pharmacists, clinical professionals, or hospitals.
What happens with special access
In January 2022, the possibility for healthcare professionals to request MDMA and psilocybin through the Special Access Program was restored, intended for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or are unavailable. For this circuit to function, Health Canada maintained a class exemption that authorized licensed professionals, hospital staff, pharmacists, and distributors to possess, administer, and dispense these substances once the program had authorized their sale.
The impact analysis indicates that the new regulation incorporates these authorizations and that, on the day it came into effect, Health Canada revoked the class exemptions and announced it publicly. In the articles, Section 6 allows the possession of restricted drugs from Part 1 of Schedule 4, among others, to professionals named in an authorization letter and to the person who has obtained the drug for their own use from a professional named in that letter.
Schedule 4 includes psilocybin, psilocin, DMT, and mescaline (with the exception of peyote), as well as various amphetamines such as MDMA.
What it implies
The change is primarily architectural: it organizes into one text what was previously scattered and prevents special access from depending on a temporary exemption. The impact analysis notes that several consultation participants requested to ensure the continuity of the general exemption for patients, professionals, and pharmacists, which was set to expire on September 30, 2026. The entry into force of the new text arrives just one day after that expiration.
Neither the regulation nor its impact analysis announces new access pathways or changes to the program’s criteria, so it is best not to confuse this reorganization with a liberalization. The practical effect for patients and clinics will depend on how Health Canada applies the text. In other countries, frameworks are also being adjusted: we have already covered how Australia relaxed the rules for psilocybin and MDMA therapy. More context on the state of clinical research can be found in our psychedelics guide.
Source
- Government of Canada. Controlled Substances Regulations (SOR/2025-242). Canada Gazette, Part II, Volume 159, No. 26, December 17, 2025.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
